Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.
|Titolo:||Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis|
|Parole Chiave:||Cytokines; JC virus; Natalizumab; Adult; Antibodies, Viral; Cytokines; Female; Follow-Up Studies; Humans; Immunologic Factors; Intercellular Signaling Peptides and Proteins; JC Virus; Male; Multiple Sclerosis; Natalizumab; T-Lymphocyte Subsets; Time Factors; Immunology and Allergy; Immunology; Neurology; Neurology (clinical)|
|Settore Scientifico Disciplinare:||Settore MED/07 - Microbiologia e Microbiologia Clinica|
|Progetto:||Tecnologie OMICS e Systems Biology per la definizione di nuove strategie finalizzate al controllo delle infezioni virali|
|Data di pubblicazione:||15-set-2017|
|Digital Object Identifier (DOI):||10.1016/j.jneuroim.2017.06.012|
|Appare nelle tipologie:||01 - Articolo su periodico|